Prevalence of human papillomavirus types 6, 11, 16 and 18 in young Austrian women - Baseline data of a phase III vaccine trial

Wiener Klinische Wochenschrift

Volumn 120, Issue 21-22, 2008, Pages 666-671

  Six, Lucia ^a,c   Leodolter, Sepp ^a   Sings, Heather L ^b   Barr, Eliav ^b   Haupt, Richard ^b   Joura, Elmar A ^a  

^a UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Universitätsfrauenklinik Wien ^*  (Austria)

Author keywords

Abnormal cervical cytology; HPV infection; HPV related anogenital disease; Prevalence; Prophylactic HPV vaccination

Indexed keywords

SILGARD; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; AUSTRIA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; PREVALENCE; SEROLOGY; SEXUAL BEHAVIOR; UTERINE CERVIX CYTOLOGY; VIRUS INFECTION; ALPHAPAPILLOMAVIRUS; CLINICAL TRIAL; COMORBIDITY; DOUBLE BLIND PROCEDURE; ISOLATION AND PURIFICATION; MICROBIOLOGY; PAPILLOMAVIRUS INFECTIONS; PHASE 3 CLINICAL TRIAL; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SMOKING; UTILIZATION; VACCINATION; WOMEN'S HEALTH; YOUNG ADULT;

ADOLESCENT; ADULT; ALPHAPAPILLOMAVIRUS; AUSTRIA; COMORBIDITY; DOUBLE-BLIND METHOD; FEMALE; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS 6; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SMOKING; VACCINATION; WOMEN'S HEALTH; YOUNG ADULT;

EID: 58149292227     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-008-1093-3     Document Type: Article

References (39)

1. M Steben E Duarte-Franco 2007 Human papillomavirus infection: Epidemiology and pathophysiology Gynecologic Oncology 107 2 S2 S5
2. FX Bosch A Lorincz N Munoz CJLM Meijer KV Shah 2002 The causal relation between human papillomavirus and cervical cancer J Clin Pathol 55 244 265
3. DM Parkin F Bray 2006 The burden of HPV-related cancers Vaccine 24 11 25
4. N Muñoz FX Bosch S de Sanjosé R Herrero X Castellsaguë KV Shah 2003 Epidemiologic classification of human papillomavirus types associated with cervical cancer N Engl J Med 348 518 527
5. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No. 5 Version 2.0 IARC Press. www-depdb.iarc.fr/globocan/GLOBOCAN2002.HTM. Accessed March 15, 2005
6. RP Insinga AG Glass BB Rush 2004 Diagnoses and outcomes in cervical cancer screening: a population-based study Am J Obstet Gynecol 191 105 113
7. A Jemal R Tiwari T Murray A Ghafoor A Samuels E Ward E Feuer M Thun 2004 Cancer Statistics, 2004 CA Cancer J Clin 54 8 29
8. GM Clifford RK Rana S Franceschi JS Smith G Gough JM Pimenta 2005 Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer Cancer Epidemiol Biomarkers Prev 14 1157 1164
9. CJ Lacey C Lowndes K Shah 2006 Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease Vaccine 24 Suppl 3 S35 S41
10. C Vutuc T Waldhoer G Haidinger 2004 Cancer mortality in Austria: 1970-2002 Wien Klin Wochenschr 116 19-20 669 675
11. C Vutuc G Haidinger B Waldner 1999 Prevalence of self-reported cervical cancer screening and impact on cervical cancer mortality in Austria Wien Klin Wochenschr 111 354 359
12. Zechmeister I (2007) Ökonomische Evaluation der Impfung gegen humane Papillomaviren (HPV-Impfung) in Österreich. Endbericht des Ludwig Boltzmann Instituts für Health Technology Assessment (LBI-HTA) 2007; Seite 26
13. EA Joura A Losch MG Haider-Angeler G Breitenecker S Leodolter 2000 Trends in vulvar neoplasia. Increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women J Reprod Med 45 8 613 615
14. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB (2002) Cancer incidence in five continents. IRAC Scientific Publication 155, International Agency for Research on Cancer, Lyon, France 8: 606-611
15. DM Parkin F Bray 2006 Chapter 2: The burden of HPV-related cancers Vaccine 24 Suppl 3 S11 S25
16. RL Winer JP Hughes Q Feng S O'Reilly NB Kiviat KK Holmes 2006 Condom use and the risk of genital human papillomavirus infection in young women N Engl J Med 354 25 2645 2654
17. DM Harper EL Franco CM Wheeler AB Moscicki B Romanowski CM Roteli-Martins 2006 Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial Lancet 367 9518 1247 1255
18. J Paavonen D Jenkins FX Bosch P Naud J Salmeron CM Wheeler 2007 Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial Lancet 369 9580 2161 2170
19. SM Garland M Hernandez-Avila CM Wheeler G Perez DM Harper S Leodolter 2007 Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases N Engl J Med 356 19 1928 1943
20. The FUTURE II Study Group 2007 Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions N Engl J Med 356 19 1915 1927
21. EA Joura S Leodolter M Hernandez-Avila CM Wheeler G Perez LA Koutsky 2007 Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16 and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three clinical trials Lancet 369 1693 1702
22. The FUTURE II Study Group 2007 Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3 and adenocarcinoma in situ: a combined analysis of four randomised clinical trials Lancet 369 1861 1868
23. SL Block T Nolan C Sattler E Barr KE Giacoletti CD Marchant 2006 Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women Pediatrics 118 5 2135 2145
24. KS Reisinger SL Block E Lazcano-Ponce R Samakoses MT Esser J Erick 2007 Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial Ped Infect Dis Journal 26 3 201 209
25. SM Garland M Steben M Hernandez-Avila LA Koutsky CM Wheeler G Perez 2007 Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines Clin Vaccine Immunol 14 6 792 795
26. S de Sanjose M Diaz X Castellsague G Clifford L Bruni N Munoz 2007 Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis Lancet Infect Dis 7 7 453 459
27. EF Dunne ER Unger M Sternberg G McQuillan DC Swan SS Patel 2007 Prevalence of HPV infection among females in the United States JAMA 297 813 819
28. A Koch A Bilina L Teodorowicz A Stary 1997 Mycoplasma hominis and Ureaplasma urealyticum in patients with sexually transmitted diseases Wien Klin Wochenschr 109 14-15 584 589
29. A Stary W Gebhart W Kopp J Soltz-Szots 1982 Genital Chlamydia infections in female patients at risk of having sexually transmitted diseases Wien Klin Wochenschr 94 18 484 487
30. J Paavonen the FUTURE II Study Group 2008 Baseline demographic characteristics of subjects enrolled in international quadrivalent HPV (types 6/11/16/18) vaccine clinical trials Curr Med Res Opin 24 6 1623 1634
31. M Plummer R Herrero S Franceschi CJ Meijer P Snijders FX Bosch 2003 Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study Cancer Causes Control 14 9 805 814
32. LA Koutsky DA Galloway KK Holmes 1988 Epidemiology of genital human papillomavirus infection Epidemiol Rev 10 122 163
33. AB Fleischer CA Parrish R Glenn SR Feldman 2001 Condylomata acuminata (genital warts) - Patient demographics and treating physicians Sex Transm Dis 28 11 643 647
34. KA Fenton CM Lowndes 2004 Recent trends in the epidemiology of sexually transmitted infections in the European Union Sex Transm Infect 80 4 255 263
35. Health Protection Agency. Focus on prevention: HIV and other sexually transmitted infections in the United Kingdom in 2003 - an update: November 2004. London, England
36. S Collins S Mazloomzadeh H Winter P Blomfield A Bailey LS Young 2002 High incidence of cervical human papillomavirus infection in women during their first sexual relationship Br J Obstet Gynaecol 109 96 98
37. SI Collins S Mazloomzadeh H Winter TP Rollason P Blomfield LS Young 2005 Proximity of first intercourse to menarche and the risk of human papillomavirus infection: a longitudinal study Int J Cancer 114 3 498 500
38. RL Winer S-K Lee JP Hughes DE Adam NB Kiviat LA Koutsky 2003 Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students Am J Epidemiol 157 3 218 226
39. The FUTURE II Study Group 2007 Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virologic evidence of HPV infection J Infect Dis 196 10 1438 1446